HOW MULTIPULSE THERAPY WORKS
How MultiPulse Therapy can potentially detect and treat atrial fibrillation (AF), rapid ventricular tachycardia (VT) and ventricular fibrillation (VF).
Advancing cardioversion and defibrillation using low-energy therapy
Cardialen, Inc. is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks.
Our MultiPulse™ Therapy (MPT) is currently being studied in an FDA-approved early feasibility IDE clinical trial exploring how a sequence of low-energy pulses timed to stop abnormal heart rhythms may restore normal heart rhythm using less energy than current high-energy shocks.
CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only
BOARD OF DIRECTORS
LEARN MORE ABOUT CLINICAL TRIALS
If you are a patient or physician interested in learning more about clinical trials, please contact us.
6160 Summit Drive North, Suite 450
Minneapolis, Minnesota 55430
Interested in joining the Cardialen team?
Please complete the form.